Experimental cholesterol drugs cut heart risk, but questions remain

March 15, 2015 3:00 PM

2 0

San Diego, March 15 (Reuters) - Studies of a new class of experimental cholesterol-lowering drugs signal that they may reduce by half the risk of heart attack and other major cardiovascular problems compared to standard treatment alone.

Doctors at the annual meeting of the American College of Cardiology, where the studies were presented, called the results "encouraging," but said larger, controlled trials were needed to fully understand the drugs, known as PCSK9 inhibitors.

Read more

To category page